Full-Time

Director – Customer Insights

Market Access

Posted on 2/21/2026

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

Compensation Overview

$180.4k - $300.7k/yr

No H1B Sponsorship

Tarrytown, NY, USA

In Person

US Citizenship, US Top Secret Clearance, Canada Citizenship, Canada Top Secret Clearance, UK Citizenship, UK Top Secret Clearance Required

Category
Growth & Marketing (1)
Requirements
  • BA/BS required
  • 12+ years of pharmaceutical/biotech commercial experience (or 10+ years with MBA/MS), in roles of increasing accountability; prior experience with market access primary research, biologic medicines and in market-leading brands is required
  • Demonstrated success in using market research to inform and influence important business decisions
  • 12+ years (or 10+ years for MBA/MS) of relevant pharmaceutical/biotech industry experience in Commercial roles with increasing responsibilities and accountabilities
  • Experience in survey design, data analysis (including secondary data), managing suppliers, presenting results, and recommending courses of action supported by research findings
  • Experience in cross-functional communication and consensus building
  • Strong technical understanding of marketing research methodologies and deep knowledge and experience across multiple complex research tools
  • Strong understanding of data sources and nomenclatures in the product development environment
  • Demonstrated knowledge of the legal and regulatory environment, as it relates to commercialization in the pharmaceutical/biotechnology industry
  • Demonstrated flexibility, leadership, influence and emotional intelligence in working across stakeholders
  • Extensive experience with managing numerous projects concurrently against stringent deadlines in a fast-paced, timeline-driven atmosphere
  • Strong analytical skills and strategic thinking ability
  • Concise and impactful written and verbal communication skills
  • Demonstrated experience in influencing and driving decision making
  • Expertise in data visualization and data storytelling of market research findings
Responsibilities
  • Lead market research plans and individual projects that inform business decisions for Regeneron’s Market Access team
  • Develop innovative Customer Insights plans that align with strategic imperatives for Market Access and Commercial Business Units (CBUs), demonstrating an ability to translate insights gaps into key business questions and inform the optimal research approach
  • Proactively recommend studies that inform critical market access decision-points and address opportunities and challenges
  • Develop and maintain a mutually beneficial partnership with stakeholders across the Market Access team, Regeneron CBUs and CSI&A; strike a balance between project rigor, timelines and ability to influence decisions
  • Manage market access research suppliers to design, scope, execute and analyze research results and develop business implications
  • Partner closely with Market Access, HEOR, Medical Affairs and other stakeholders to shape value propositions and go-to-market approaches that resonate with decision makers across the healthcare ecosystem
  • Collaborate with the Market Access team, CBUs and CSI&A colleagues to influence data capabilities and stay informed on the market access landscape, trends and competitive outlook
  • Work closely with Advanced Analytics partners to effectively measure performance of key market access initiatives via secondary data sources; address related questions from senior leadership
  • Demonstrate proficiency and drive continuous improvement in market access primary research designs and analysis (qualitative and quantitative), and develop customized innovative research solutions to address complex strategic business issues
  • Manage all market access primary research in accordance with internal compliance policies and best practices, with agreed upon preferred vendors
  • Recommend reasonable, evidence driven business-building ideas, while encouraging the use of customer and market insights to inform strategic business decisions
  • Provide support for pricing and contracting strategies, designing patient reimbursement journeys, and developing patient support programs to ensure access to Regeneron medicines and improve patient outcomes
  • Market access customer insights: lead qualitative and quantitative research with payers, providers, and policy stakeholders to understand evolving access dynamics; integrate payer insights with patient and HCP perspectives to create a holistic view of barriers to access, affordability and adoption; provide forward-looking assessments of policy changes, competitive access strategies and value-based care models; identify key drivers of customer satisfaction and loyalty to inform business strategies.
  • Pricing and contracting support: collaborate with pricing and contracting teams to incorporate customer insights into pricing strategies and negotiations; analyze competitive pricing models and market dynamics to recommend optimal pricing structures; support the development of contracting frameworks and agreements that align with customer needs and payer expectations; provide insights into value-based pricing models, reimbursement strategies and risk-sharing agreements to enhance market access outcomes.
  • Patient reimbursement journey design: map the end-to-end patient reimbursement journey to identify pain points and opportunities for improvement; work closely with payers, providers and patient advocacy groups to streamline reimbursement processes and minimize barriers to access; work to uncover solutions to address challenges such as prior authorizations, co-pay assistance and insurance coverage gaps; provide insights to enhance patient affordability programs and ensure equitable access to therapies.
  • Establish, manage and share outcomes from plans that measure and track performance against critical success factors
  • Synthesize insights and analyses from a variety of sources (marketing research, competitive intelligence, secondary data) to inform strategic choices and decisions; develop and present findings to business teams and senior management
  • Consolidate and integrate a variety of market access data and information into actionable and differentiating insights that identify business opportunities/strategies, keeping in mind broader business implications
  • Create compelling presentations that communicate complex insights in a manner that is easily understood and actioned upon
  • Recommend reasonable, evidence driven business-building ideas, while encouraging the use of customer and market insights to inform strategic business decisions
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent global sales surged 33% to $4.9B in Q1 2026, treating 1.4M patients across nine indications.
  • Libtayo net sales grew 54% to $438M in Q1 2026 from CSCC and lung cancer uptake.
  • $27B US R&D and manufacturing commitment secures three-year tariff relief via April 2026 Trump deal.

What critics are saying

  • Biosimilar aflibercept from Viatris erodes legacy EYLEA sales, dropping combined franchise 10% to $941M in Q1 2026.
  • Sanofi renegotiates Dupixent profit-sharing as sales hit $4.9B, cutting Regeneron's 25-50% economics by 2028.
  • Trump most-favored-nation deal mandates Medicaid price cuts on EYLEA and Dupixent, slashing margins 30-50% by mid-2027.

What makes Regeneron Pharmaceuticals unique

  • Proprietary VelociSuite technologies enable rapid homegrown drug discovery across modalities.
  • Developed EYLEA HD with unique 5-month dosing for wet AMD approved by FDA in Q1 2026.
  • Pioneered Otarmeni, first in vivo gene therapy for OTOF-related hearing loss, FDA-approved April 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Endpoints News
Apr 13th, 2026
Regeneron wades into radiopharma through $40M upfront deal with telix.

Regeneron wades into radiopharma through $40M upfront deal with telix. News reporter. Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Think Endpoints Company is worth reading - tell google. Confirm Endpoints as a trusted biopharma news source ENDPOINTS CAREERS TCG stealth clinic-ready newco.

AllSci
Apr 13th, 2026
Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal.

Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal. April 13, 2026 Australia-based Telix Pharmaceuticals Ltd (ASX: TLX, Nasdaq: TLX) and US firm Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced a strategic collaboration to jointly develop and commercialize next-generation antibody-based radiopharmaceutical therapies across multiple solid tumor indications. The agreement pairs Telix's radiopharmaceutical development platform and global manufacturing infrastructure with Regeneron's antibody discovery technologies, including its VelocImmune and VelociSuite platforms, to generate a pipeline of radiolabeled biologics. Specific tumor targets have not been disclosed. Deal specifics. Under the deal terms, Telix will receive an upfront payment of USD 40 million from Regeneron for access to its radiopharmaceutical manufacturing platform across four initial therapeutic programs. Should Telix elect to opt out of co-funding on any individual program, it becomes eligible to receive up to USD 535 million in development and commercial milestone payments per program, plus low double-digit royalties on net sales, with an aggregate milestone ceiling of USD 2.1 billion across all programs. Where Telix remains in the co-funding model, the two companies will share equally in global development costs and commercialization profits on a 50/50 basis, with Telix retaining the option to co-promote certain products. The collaboration covers four initial therapeutic programs, with Regeneron holding the option to expand to four additional programs subject to further upfront payments. The parties will also jointly develop radio-diagnostic assets to support patient selection and treatment response monitoring, with Telix leading commercialization of those diagnostics and Regeneron receiving a defined percentage of profits. The exact percentage was not disclosed. The structure gives Telix a per-program election right at a defined decision point: co-fund and share in global profits equally, or opt out and revert to a milestone-plus-royalty economics model. This optionality allows Telix to allocate capital selectively depending on program progression and resource constraints, while preserving upside participation across the portfolio. The agreement is global in scope, with no geographic carve-outs or territorial allocations disclosed. No equity investment by either party in the other was announced in connection with the transaction. The drug programs will combine Regeneron's antibody targeting components, drawn from its portfolio of antibodies generated through VelocImmune mice, with Telix's radiolabeling and manufacturing capabilities. The modality class is antibody-based radiopharmaceutical therapy, in which a tumor-antigen-binding antibody serves as the targeting vehicle for a therapeutic radionuclide payload. The collaboration also encompasses potential bispecific antibody formats, given Regeneron's established expertise in that area. Regeneron noted in its public commentary that it intends to explore these agents as monotherapy and in rational combination with its immunotherapy platform, citing lung cancer as one area of interest where its PD-1 inhibitor is already in use. The specific antigens, antibody names, and radionuclide payloads for the collaboration programs have not been publicly identified. The theranostic component of the agreement, pairing matched diagnostic and therapeutic agents using the same antibody targeting vector, supports patient stratification and dosimetry assessment ahead of and during treatment. Telix will lead commercialization of the diagnostic assets developed under the collaboration. Strategic implications. Regeneron's entry into radiopharmaceutical oncology drug development marks a modality expansion for a company whose oncology portfolio has been anchored in antibody-based immunotherapy. The company indicated it views targeted radiopharmaceuticals as a frontier in oncology and has framed the collaboration as an opportunity to apply its antibody discovery engine to a delivery modality it has not previously pursued commercially. For Telix, the arrangement provides validation of its radiopharmaceutical manufacturing infrastructure as a platform asset capable of attracting large-scale co-development partnerships. Telix's existing commercial radiopharmaceutical portfolio includes Illuccix kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC injection (also known as 68Ga-PSMA-11 injection), approved by the US FDA as a prostate cancer imaging agent. In addition, the firm announced on April 9, 2026, that the US FDA has accepted an NDA filing for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer). Your email address will not be published. Required fields are marked *

GlobalData
Apr 13th, 2026
Telix and Regeneron to co-develop radiopharmaceutical therapies.

Telix and Regeneron to co-develop radiopharmaceutical therapies. The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses. Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global manufacturing and supply chain infrastructure with Regeneron's biologics knowledge, particularly in bispecific antibody discovery. Regeneron will initially provide Telix with an upfront cash payment of $40m for access to the latter's radiopharmaceutical manufacturing platform for four therapeutic initiatives. There is an option for Regeneron to expand to another four programmes, which would involve further upfront payments. Both companies will equally share the costs and potential profits worldwide, with Telix optionally co-promoting certain products. If Telix chooses to step back from funding a specific programme, it could gain up to $535m in developmental and commercial milestones, in addition to low double-digit royalties on subsequent net sales. Regeneron oncology and antibody technology research senior vice-president John Lin said: "At Regeneron, Pharmaceutical Technology follow the science to determine the best therapeutic approach for each disease, continuously expanding its toolbox of treatment modalities - from monoclonal and bispecific antibodies to cell therapies and beyond. "Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need." The collaboration will include several solid tumour targets from Regeneron's antibody portfolio, benefiting from its VelocImmune mice technology. It reflects a joint focus on precision oncology, seeking to enhance patient selection and assess treatment responses through new radio-diagnostics. The companies also plan to develop diagnostic assets, where Telix will spearhead the commercialisation efforts, and Regeneron will receive a predetermined share of the profits. In December 2025, Regeneron teamed up with Tessera Therapeutics to develop and commercialise Tessera's rare disease in vivo gene writing programme, TSRA-196. Give your business an edge with its leading industry insights.

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

INACTIVE